GlassScriptPhysician profile
Dushyant Verma
NPI 1164477014
$1,570.82
in general payments reported to CMS, 2019-2025
27 companies · $471 in 2025
The $471 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $61.95 · 2020: $110 · 2021: $50.99 · 2022: $206 · 2023: $314 · 2024: $357 · 2025: $471.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $967 · Education: $175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $967.01 |
| Education | $175.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $214.21 | 2022-2025 | Rybrevant, Carvykti, Darzalex |
| Intuitive Surgical, INC. | $150.02 | 2023 | |
| Abbott Laboratories | $149.62 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $114.81 | 2024-2025 | Opdualag, Opdivo |
| Celgene Corporation | $110.09 | 2023-2025 | Reblozyl, Pomalyst |
| Aveo Pharmaceuticals, INC. | $104.36 | 2023-2025 | Fotivda |
| Astellas Pharma US INC | $95.00 | 2020 | |
| Incyte Corporation | $83.99 | 2024 | |
| Merck Sharp & Dohme LLC | $81.68 | 2024-2025 | Keytruda, Lynparza |
| Novartis Pharmaceuticals Corporation | $60.23 | 2022-2024 | |
| Abbvie INC. | $48.92 | 2023-2025 | Venclexta |
| Medtronic, INC. | $38.87 | 2021 | |
| Pharmacyclics LLC, An Abbvie Company | $30.96 | 2019-2023 | Epkinly |
| Foundation Medicine, INC. | $26.92 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $26.32 | 2025 | Imfinzi |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exelixis INC. | $26.18 | 2025 | Cabometyx |
| Daiichi Sankyo INC. | $26.18 | 2025 | Enhertu |
| Genentech USA, INC. | $24.89 | 2024 | Alecensa, Tecentriq |
| Lilly USA, LLC | $23.56 | 2019 | |
| Pharmacosmos Therapeutics INC. | $22.41 | 2025 | Monoferric |
| Gilead Sciences, INC. | $21.46 | 2025 | Trodelvy |
| Rigel Pharmaceuticals, INC. | $18.49 | 2025 | Rezlidhia, Gavreto, Tavalisse |
| Glaxosmithkline, LLC. | $15.81 | 2025 | Jemperli, Zejula |
| Pfizer INC. | $14.92 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.87 | 2020 | |
| Acrotech Biopharma INC. | $13.93 | 2022 | |
| Dendreon Pharmaceuticals LLC | $12.12 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dushyant Verma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.